[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
John Militello, an officer of Rocket Pharmaceuticals, Inc. (RCKT), reported a sale of 7,043 shares of common stock on 08/14/2025 at a price of $3.019 per share. The filing states the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units that convert one-for-one into common stock. After the reported transaction, the reporting person beneficially owned 56,984 shares, reported as direct ownership. His roles are listed as Vice President of Finance, Treasurer and Principal Accounting Officer. The Form 4 was signed by an attorney-in-fact, Martin Wilson, on 08/18/2025.
John Militello, dirigente di Rocket Pharmaceuticals, Inc. (RCKT), ha venduto 7.043 azioni di azioni ordinarie il 14/08/2025 al prezzo di $3,019 per azione. La comunicazione indica che la vendita 猫 stata effettuata per ottemperare a obblighi di ritenuta fiscale derivanti dal consolidamento di restricted stock unit convertite uno a uno in azioni ordinarie. Dopo l鈥檕perazione segnalata, il dichiarante deteneva beneficiariamente 56.984 azioni, riportate come propriet脿 diretta. I suoi incarichi sono Vice President of Finance, Tesoriere e Principal Accounting Officer. Il Modulo 4 猫 stato firmato per procura dall鈥檃vvocato-in-fatto Martin Wilson il 18/08/2025.
John Militello, funcionario de Rocket Pharmaceuticals, Inc. (RCKT), registr贸 la venta de 7.043 acciones ordinarias el 14/08/2025 a $3,019 por acci贸n. El documento indica que la venta se realiz贸 para cubrir obligaciones de retenci贸n fiscal originadas por la consolidaci贸n de unidades de acciones restringidas que se convierten una a una en acciones ordinarias. Tras la transacci贸n informada, la persona declarada pose铆a beneficiariamente 56.984 acciones, consignadas como propiedad directa. Sus cargos figuran como Vice President of Finance, Tesorero y Principal Accounting Officer. El Formulario 4 fue firmado por apoderado, Martin Wilson, el 18/08/2025.
John Militello電� Rocket Pharmaceuticals, Inc.(RCKT)鞚� 鞛勳洂鞙茧靹� 2025-08-14鞐� 氤错喌欤� 7,043欤�毳� 欤茧嫻 $3.019鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 鞝滍暅欤检嫕雼渼(RSU)鞚� 氩犾姢韺呾溂搿� 鞚疙暣 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅橂姅 欤检嫕鞐� 雽�頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 頃措嫻 毵る弰臧� 鞚措（鞏挫雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 頉� 鞁犼碃鞚胳潃 56,984欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 歆侅爲 靻岇湢搿� 氤搓碃霅橃棃鞀惦媹雼�. 攴胳潣 歆侅眳鞚� 鞛 攵�靷灔(Vice President of Finance), 鞛雼措嫻(Treasurer) 氚� 靾橃劃 須岅硠毂呾瀯鞛�(Principal Accounting Officer)搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑 Martin Wilson鞚� 2025-08-18鞐� 靹滊獏頄堨姷雼堧嫟.
John Militello, cadre de Rocket Pharmaceuticals, Inc. (RCKT), a d茅clar茅 la vente de 7 043 actions ordinaires le 14/08/2025 au prix de 3,019 $ par action. Le dossier indique que la vente a 茅t茅 effectu茅e pour satisfaire des obligations de retenue fiscale r茅sultant du vesting d鈥檜nit茅s d鈥檃ctions restreintes converties 脿 hauteur d鈥檜ne action ordinaire par unit茅. Apr猫s la transaction signal茅e, la personne d茅clarante poss茅dait b茅n茅ficiairement 56 984 actions, d茅clar茅es en propri茅t茅 directe. Ses fonctions sont Vice President of Finance, Tr茅sorier et Principal Accounting Officer. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire, Martin Wilson, le 18/08/2025.
John Militello, ein leitender Angestellter von Rocket Pharmaceuticals, Inc. (RCKT), meldete den Verkauf von 7.043 Aktien Stammaktien am 14.08.2025 zu einem Preis von $3,019 pro Aktie. Die Einreichung gibt an, dass der Verkauf zur Erf眉llung von steuerlichen Einbehaltspflichten erfolgte, die aus dem Vesting von Restricted Stock Units resultieren, die 1:1 in Stammaktien umgewandelt werden. Nach der gemeldeten Transaktion besa脽 die meldende Person wirtschaftlich 56.984 Aktien, angegeben als Direkteigentum. Seine Funktionen sind Vice President of Finance, Treasurer und Principal Accounting Officer. Das Formblatt 4 wurde am 18.08.2025 von einem Bevollm盲chtigten, Martin Wilson, unterschrieben.
- Sale was disclosed as tax withholding for RSU vesting, which is a common, non-speculative reason for insider sales
- Reporting person retains 56,984 shares after the transaction, showing continued ownership interest
- None.
Insights
TL;DR Insider sold a small number of shares to cover taxes from RSU vesting; ownership remains notable but no operational signal.
The reported sale of 7,043 shares at $3.019 appears to be a routine withholding sale linked to RSU vesting rather than a discretionary cash-raising sale. The filing shows the reporting person continues to hold 56,984 shares directly, indicating retained exposure to the issuer. For investors, this is a non-event from a company-performance perspective because it documents a tax-related disposition rather than a strategic liquidation. Volume and value of the sale are modest relative to typical market-cap impacts for public companies.
TL;DR Transaction aligns with standard insider tax-withholding practice; disclosure and filing appear complete.
The Form 4 explicitly notes the sale was to satisfy tax withholding on vested RSUs and includes role disclosure for the reporting person. The form lists the date of transaction and post-transaction beneficial ownership, and it is signed by an attorney-in-fact, meeting procedural requirements. No indications of late amendment or unexplained transfers are present in the provided text.
John Militello, dirigente di Rocket Pharmaceuticals, Inc. (RCKT), ha venduto 7.043 azioni di azioni ordinarie il 14/08/2025 al prezzo di $3,019 per azione. La comunicazione indica che la vendita 猫 stata effettuata per ottemperare a obblighi di ritenuta fiscale derivanti dal consolidamento di restricted stock unit convertite uno a uno in azioni ordinarie. Dopo l鈥檕perazione segnalata, il dichiarante deteneva beneficiariamente 56.984 azioni, riportate come propriet脿 diretta. I suoi incarichi sono Vice President of Finance, Tesoriere e Principal Accounting Officer. Il Modulo 4 猫 stato firmato per procura dall鈥檃vvocato-in-fatto Martin Wilson il 18/08/2025.
John Militello, funcionario de Rocket Pharmaceuticals, Inc. (RCKT), registr贸 la venta de 7.043 acciones ordinarias el 14/08/2025 a $3,019 por acci贸n. El documento indica que la venta se realiz贸 para cubrir obligaciones de retenci贸n fiscal originadas por la consolidaci贸n de unidades de acciones restringidas que se convierten una a una en acciones ordinarias. Tras la transacci贸n informada, la persona declarada pose铆a beneficiariamente 56.984 acciones, consignadas como propiedad directa. Sus cargos figuran como Vice President of Finance, Tesorero y Principal Accounting Officer. El Formulario 4 fue firmado por apoderado, Martin Wilson, el 18/08/2025.
John Militello電� Rocket Pharmaceuticals, Inc.(RCKT)鞚� 鞛勳洂鞙茧靹� 2025-08-14鞐� 氤错喌欤� 7,043欤�毳� 欤茧嫻 $3.019鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 鞝滍暅欤检嫕雼渼(RSU)鞚� 氩犾姢韺呾溂搿� 鞚疙暣 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅橂姅 欤检嫕鞐� 雽�頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 頃措嫻 毵る弰臧� 鞚措（鞏挫雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 頉� 鞁犼碃鞚胳潃 56,984欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 歆侅爲 靻岇湢搿� 氤搓碃霅橃棃鞀惦媹雼�. 攴胳潣 歆侅眳鞚� 鞛 攵�靷灔(Vice President of Finance), 鞛雼措嫻(Treasurer) 氚� 靾橃劃 須岅硠毂呾瀯鞛�(Principal Accounting Officer)搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑 Martin Wilson鞚� 2025-08-18鞐� 靹滊獏頄堨姷雼堧嫟.
John Militello, cadre de Rocket Pharmaceuticals, Inc. (RCKT), a d茅clar茅 la vente de 7 043 actions ordinaires le 14/08/2025 au prix de 3,019 $ par action. Le dossier indique que la vente a 茅t茅 effectu茅e pour satisfaire des obligations de retenue fiscale r茅sultant du vesting d鈥檜nit茅s d鈥檃ctions restreintes converties 脿 hauteur d鈥檜ne action ordinaire par unit茅. Apr猫s la transaction signal茅e, la personne d茅clarante poss茅dait b茅n茅ficiairement 56 984 actions, d茅clar茅es en propri茅t茅 directe. Ses fonctions sont Vice President of Finance, Tr茅sorier et Principal Accounting Officer. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire, Martin Wilson, le 18/08/2025.
John Militello, ein leitender Angestellter von Rocket Pharmaceuticals, Inc. (RCKT), meldete den Verkauf von 7.043 Aktien Stammaktien am 14.08.2025 zu einem Preis von $3,019 pro Aktie. Die Einreichung gibt an, dass der Verkauf zur Erf眉llung von steuerlichen Einbehaltspflichten erfolgte, die aus dem Vesting von Restricted Stock Units resultieren, die 1:1 in Stammaktien umgewandelt werden. Nach der gemeldeten Transaktion besa脽 die meldende Person wirtschaftlich 56.984 Aktien, angegeben als Direkteigentum. Seine Funktionen sind Vice President of Finance, Treasurer und Principal Accounting Officer. Das Formblatt 4 wurde am 18.08.2025 von einem Bevollm盲chtigten, Martin Wilson, unterschrieben.
FAQ
What did John Militello report on the Form 4 for RCKT?
How many shares does the reporting person own after the transaction?
Why were the shares sold according to the filing?
What positions does John Militello hold at Rocket Pharmaceuticals?
When was the Form 4 signed and by whom?
